IDEXX Announces New Program to Help Advance Care for Cats

WESTBROOK, Maine, March 14, 2014 — IDEXX Laboratories (NASDAQ: IDXX) has launched the Advance Care for Cats pilot program to address veterinarians’ overwhelming demand to improve feline care in their practices. According to a 2013 Bayer study, 78% of veterinarians say there is a significant opportunity to enhance the care given to feline companions. The IDEXX pilot is designed to assess if the program improves feline care and/or increases feline business within participating practices. In the coming months, IDEXX will be evaluating the results to determine if and when to make the program available to more practices. The Advance Care for Cats pilot program is providing hands-on support, protocol guidance and educational resources to a select group of practices and features three important feline diagnostic innovations.

IDEXX simultaneously introduced the SNAP Feline proBNP Test and the Catalyst fructosamine slide. These tests join the SNAP Feline Triple Test, giving practitioners three powerful feline diagnostics to address common chronic feline ailments. Now veterinary practices can provide diagnostic results for heart disease, diabetes and the most common infectious diseases during the patient visit.

“Cats are good at hiding illnesses, so finding out what’s wrong can be a long, frustrating and worrisome process for pet owners,” says Jonathan W. Ayers, Chairman, President and Chief Executive Officer of IDEXX Laboratories. “With these three innovations, veterinarians can provide answers and treatment plans before pet owners leave the practice. This significantly increases the likelihood that pet owners will comply with veterinary recommendations, which will improve the lives of feline family members and strengthen the bonds between veterinarians and their clients.”

A summary of the three featured feline diagnostics:

• SNAP Feline proBNP Test lets veterinarians assess the stretch and stress of the heart during the patient visit using the most stable cardiac biomarker (NTproBNP).
• Catalyst fructosamine slide gives veterinarians the information they need to manage diabetes with confidence using the Catalyst Dx Chemistry Analyzer or the Catalyst One™ Chemistry Analyzer.
• SNAP Feline Triple Test provides infectious disease results for FIV, FELV and feline heartworm, all from a single blood draw and at the same cost as the SNAP FIV/FeLV Combo Test.

For more information about these feline advances or other products and services from IDEXX, visit idexx.com.

About IDEXX Laboratories. Inc.
IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. IDEXX is also a worldwide leader in providing livestock and poultry diagnostic tests and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 5,500 people and offers products to customers in more than 175 countries.

Note Regarding Forward-Looking Statements
This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “expects,” “may,” “anticipates,” “intends,” “would,” “will,” “plans,” “believes,” “estimates,” “should,” and similar words and expressions. These forward-looking statements are based on management's current expectations and beliefs, as well as a number of assumptions concerning future events. These statements are subject to risks, uncertainties, assumptions and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by the Company pursuant to United States securities laws contain discussions of these risks and uncertainties. The Company assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are advised to review the Companyʼs filings with the United States Securities and Exchange Commission (which are available from the SECʼs EDGAR database at sec.gov, at various SEC reference facilities in the United States and via the Company's website at idexx.com).

Contact

IDEXX Laboratories
David Eaton
Senior Programs Manager, Direct Marketing
1-207-318-1352

david-eaton@idexx.com